Luca Benatti / Chief Executive Officer
Dr Luca Benatti is the Chief Executive Officer since June 2012. He has over 25 year experience in Pharma and Biotech. He was Co-founder and CEO of Newron Pharmaceuticals (NWRN, Swiss Stock Exchange). Under his guidance, Newron developed a pipeline of innovative therapies including Xadago, approved worldwide for the treatment of Parkinson's disease. Luca graduated and performed his post-doctoral training at Milano Genetics Institute. He is an independent Board member at Intercept Pharmaceuticals (ICPT, Nasdaq), Newron Pharmaceuticals, Chairman of the Italian Angels for Biotech, Member of the Strategic Advisory Board of Zambon, Member of the Board of Assobiotec, member of the Jury of the European Biotechnica Award and of the Open Accelerator Award. He has authored several scientific publications and holds numerous patents.
Mauro Magnani / Chief Scientific Officer
Prof. Mauro Magnani is the Company co-founder and Chief Scientific Officer and Director since 2007. He is Professor of Biochemistry and Director of the Centre of Biotechnology, at the University of Urbino, Italy.
Prof. Magnani is an international leader in the development of drug delivery technologies using red blood cells. During his academic career he has been: Visiting Researcher, Dept. Biochemistry, Univ. Birmingham, 1980; Visiting Prof. Dept. Biology, Haifa, Israel. Since 1986 he is Full Professor of Biochemistry ; Dean, Faculty of Sciences University of Urbino 1995-2001; Director Interuniversity Consortium for Biotechnology (CIB) 1998-2004; Vice Rector of the University of Urbino 2001-2009. He is also a "Technical Director" nominated by the "Agenzia Italiana del Farmaco, AIFA" with n. AIDT-19/2005. Co-founder of various start-up companies, and author of more than 400 papers published in international refereed scientific journals and inventor of numerous patents; Co-editor of three books and reviewer for over 30 international Journals.
Guenter R. Janhofer / Chief Medical Officer
Guenter R. Janhofer is the Chief Medical Officer since February 2018. He has spent more than 30 years in the healthcare industry in roles of increasing complexity and scope. Before joining Erydel, Guenter served as the Head of Development and then Chief Medical Officer at BTG, a British healthcare company specialized in interventional medicine across a broad spectrum of disease areas, ranging from interventional oncology to pulmonology to vascular diseases, and comprising drugs, biologicals and drug device combinations. Guenter was responsible for the successful completion of the clinical development program of several compounds and subsequent regulatory approval by the FDA. Prior to his tenure at BTG, Guenter had a career at Merck, Inc., both in European subsidiaries as the respective Medical Director as well as at Merck’s US headquarters as Vice President for Global Medical and Scientific Affairs. He received his MD from the University of Hamburg, Germany, and holds PhDs in Climatology and Medicine as well as a post doc degree (Habilitation) from the University of Technology in Berlin.
Giovanni Mambrini / Chief Operating Officer
Dr Giovanni Mambrini is the Chief Operating Officer and co-founder of the Company. Giovanni previously served as our Head of Medical Devices from 2012 through 2017 and joined EryDel in 2008 as General Manager. Dr Mambrini gained over 20 year experience in medical device technology within multinational Companies and developed products for blood processing, cardiac surgery, anesthesia, intensive care, combination products and advanced therapies. Prior to joining EryDel, he was Manager of R&D at Covidien (from 1998 to 2002), Scientific Affair Manager at Dideco (from 2002 to 2005); Leader of "Biocompatibility & Biosensors, Centre for Innovation and Technological Excellence" at Sorin Group Italia (from 2005 to 2008).
Ronan W. Gannon / Chief Commercial Officer
Ronan W. Gannon joined EryDel S.p.A. as Chief Commercial Officer in October 2018. He brings more than 25 years of industry experience across large, midsize and startup life science companies. Before joining EryDel, Ronan led global commercial operations at Radius Health, where he helped transform the company from a late-stage development startup into a fully integrated biopharmaceutical company. Prior to that, Ronan spent ten years at CSL Behring where he held several leadership roles including US Vice President Marketing and North America general management roles in the US and Canada. During his tenure at CSL Behring he launched six orphan drugs. Prior to CSL, Ronan led sales and marketing teams at Zeneca Pharmaceuticals, and GlaxoSmithKline across several therapeutic areas including biologicals, oncology, and asthma. He received an MBA from Northeastern University, a BA from the University of Richmond and holds alumni status from the Harvard Business School.
Stan Musial / Chief Financial Officer
Stanley J. Musial joined EryDel S.p.A. as its Chief Financial Officer in November 2018. Before joining EryDel, Stan held the position of Executive Vice President and Chief Financial Officer of Egalet (NASDAQ: EGLT), a commercial stage, fully integrated specialty pharmaceutical company focused on innovative treatments for pain, from 2014 to 2018. Stan took Egalet public in 2014, and was part of a team that transformed the company from development stage to revenue generation. Prior to Egalet, Stan held the position of Chief Financial Officer at Prism Pharmaceuticals, Inc., Strategic Diagnostics, Inc., and positions with other biotechnology, medical device and healthcare services companies. Mr. Musial began his career with KPMG LLP, a professional services company, and received a B.S. in accounting from the Pennsylvania State University and an M.B.A. from Temple University. He is a certified public accountant in the Commonwealth of Pennsylvania.
Alyssa Wyant / SVP, Regulatory Affairs
Alyssa Wyant joined EryDel S.p.A. as Senior Vice President, Regulatory Affairs in January 2019. Alyssa has over 20 years of global regulatory experience with a focus on the development, registration and successful launches of innovative, biologic and small molecule orphan disease products. Prior to joining EryDel, Alyssa served on the management team at Edge Therapeutics from 2017 to 2018 as Senior Vice President, Regulatory Affairs, where she was responsible for the development of a treatment for aneurysmal subarachnoid hemorrhage. Previous positions included serving as Vice President, Global Regulatory Affairs at PTC Therapeutics from 2015 to 2017, where she oversaw the international regulatory activities for a product treating several orphan disease indications, including Duchenne muscular dystrophy and cystic fibrosis. As Senior Director, International Regulatory Affairs at NPS Pharmaceuticals from 2012 to 2015, she supported FDA approval for an orphan product for hypoparathyroidism, and oversaw the U.S. and EU launches of another orphan product for short bowel syndrome. Alyssa also held multiple leadership positions in global regulatory affairs over a 9-year period at Shire Human Genetic Therapies in the U.S. and Switzerland, where she was a key contributor in obtaining, maintaining, and extending registration of 3 enzyme replacement therapies for orphan diseases. Ms. Wyant has a B.S. in cell and molecular biology from the University of Washington.